Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer.

Trial Profile

Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Oct 2012

At a glance

  • Drugs Paclitaxel (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Taxanes
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 08 Dec 2011 Planned end date changed from 1 Dec 2011 to 1 Sep 2013 as reported by ClinicalTrials.gov.
    • 01 Jun 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top